» Articles » PMID: 25154322

The Survival of Patients with High Grade Glioma from Different Ethnic Groups in South East England

Overview
Journal J Neurooncol
Publisher Springer
Date 2014 Aug 27
PMID 25154322
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Studies in the United States (US) have reported varying treatment and survival for patients with high grade glioma from different ethnic groups. This study investigates for the first time whether differences also exist in the United Kingdom (UK). This population-based cohort study used cancer registration data for 4,845 patients diagnosed in South East England between 2000 and 2009. Linked self-assigned ethnicity data within Hospital Episode Statistics were used to define White, Indian, Pakistani, Bangladeshi, Black Caribbean, Black African, Other and Not known groups. Logistic regression was used to generate odds ratios for a record of receipt of treatment (surgery, radiotherapy and chemotherapy), adjusting for sex, age, morphology, socioeconomic deprivation and comorbidity in each ethnic group. Hazard ratios were generated using Cox regression, adjusting for sex, age, morphology, socioeconomic deprivation, comorbidity and treatment. The overall one-year survival was 28.4 %. Ethnicity data was available for 3,793 (78 %) patients. Receipt of treatment was generally similar between different ethnic groups after adjustment for sex, age, morphology, socioeconomic deprivation and comorbidity. After adjustment for potential confounders, the Indian (HR 0.72, p = 0.037) and Other groups (HR 0.76, p = 0.003) had better survival, while the Not known group (HR 1.34, p < 0.0001) had worse survival than the White group. Patients from UK Indian groups have better survival than White patients while those from Black ethnic groups appear to have similar survival to White patients. These findings suggest the need to investigate possible contributing factors including the completeness of follow-up, clinical performance status and tumour biology.

Citing Articles

High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma.

Pohlmann J, Weller M, Marcellusi A, Grabe-Heyne K, Krott-Coi L, Rabar S Front Oncol. 2024; 14:1368606.

PMID: 38571509 PMC: 10987841. DOI: 10.3389/fonc.2024.1368606.


The Influence of Ethnicity on Survival from Malignant Primary Brain Tumours in England: A Population-Based Cohort Study.

Wanis H, Moller H, Ashkan K, Davies E Cancers (Basel). 2023; 15(5).

PMID: 36900254 PMC: 10000771. DOI: 10.3390/cancers15051464.


Comparison of dual-time point 18F-FDG PET/CT tumor-to-background ratio, intraoperative 5-aminolevulinic acid fluorescence scale, and Ki-67 index in high-grade glioma.

Kim Y, Cho K, Jang S Medicine (Baltimore). 2019; 98(8):e14397.

PMID: 30813140 PMC: 6408082. DOI: 10.1097/MD.0000000000014397.


Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?.

Vasaikar S, Tsipras G, Landazuri N, Costa H, Wilhelmi V, Scicluna P BMC Cancer. 2018; 18(1):154.

PMID: 29409474 PMC: 5801893. DOI: 10.1186/s12885-018-4012-7.

References
1.
Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

2.
Pobereskin L, Chadduck J . Incidence of brain tumours in two English counties: a population based study. J Neurol Neurosurg Psychiatry. 2000; 69(4):464-71. PMC: 1737141. DOI: 10.1136/jnnp.69.4.464. View

3.
Zanotto-Filho A, Coradini K, Braganhol E, Schroder R, de Oliveira C, Simoes-Pires A . Curcumin-loaded lipid-core nanocapsules as a strategy to improve pharmacological efficacy of curcumin in glioma treatment. Eur J Pharm Biopharm. 2012; 83(2):156-67. DOI: 10.1016/j.ejpb.2012.10.019. View

4.
Bullard J, Coleman M, Robinson D, Lutz J, Bell J, Peto J . Completeness of cancer registration: a new method for routine use. Br J Cancer. 2000; 82(5):1111-6. PMC: 2374436. DOI: 10.1054/bjoc.1999.1048. View

5.
McKinney P . Brain tumours: incidence, survival, and aetiology. J Neurol Neurosurg Psychiatry. 2004; 75 Suppl 2:ii12-7. PMC: 1765660. DOI: 10.1136/jnnp.2004.040741. View